Literature DB >> 28162967

Development and validation of a LC-MS/MS assay for quantification of cisplatin in rat plasma and urine.

Abdul Naveed Shaik1, Deborah A Altomare2, Lawrence J Lesko1, Mirjam N Trame3.   

Abstract

Till date, no analytical method published to detect Cisplatin has been validated according to the U.S. Food and Drug Administration (FDA) guidance using liquid chromatography mass spectrometry (LC-MS/MS). We report, a validated LC-MS/MS method for quantitative determination of cisplatin in rat plasma and urine according to FDA guidlines. Cisplatin is a platinum containing compound used for the treatment of different types of cancers. Quantitative determination of cisplatin has been carried out using atomic absorption spectroscopy, high pressure liquid chromatography with phosphorescence, ultra-violet detection, or with inductively coupled plasma mass spectrometry. Few LC-MS/MS methods have been reported for the analysis of cisplatin either for direct quantification or indirect by derivatizing with organic compounds but none of the reported methods have validated the method. The developed and validated assay presented here is a highly sensitive LC-MS/MS method developed and validated for the quantitative determination of cisplatin following derivatization with diethyldithiocarbamate (DDTC) in order to detect platinum (Pt) of cisplatin, suitable for pharmacokinetic studies in rats and to further use it to study human toxicology. Chromatographic separation was achieved using a Poroshell 120 EC-C18 column (3×50mm, 2.7μm) with a binary gradient mobile phase. Quantification was performed on a triple quadruple with electrospray ionization and detection was performed using multiple reaction monitoring. The method has a limit of detection of 1ng/mL, and the quantifiable range was 3-3000ng/mL in rat plasma and urine. The method was accurate and precise with an accuracy and precision for intra-day and inter-day of ±20% for lower limit of quantitation and of ±15% for low, mid and high quality control samples. This method was successfully applied to study the pharmacokinetic profile of cisplatin in rat plasma and urine given a range of doses from 0.5 to 3.5mg/kg. Published by Elsevier B.V.

Entities:  

Keywords:  Cisplatin; Cisplatin derivatization with DDTC; Cisplatin rat pharmacokinetics; FDA method validation; LC–MS/MS; Non-compartmental analysis of cisplatin

Mesh:

Substances:

Year:  2016        PMID: 28162967     DOI: 10.1016/j.jchromb.2016.11.027

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

1.  Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients.

Authors:  Yanshuo Cao; Qing Chang; Michael Cabanero; Wenjiang Zhang; Sara Hafezi-Bakhtiari; David Hedley; Gail Darling; Fayez Quereshy; Raymond Jang; Elena Elimova; Jennifer Knox; Olga Ornatsky; Stefano Serra; Eric Chen
Journal:  J Gastrointest Cancer       Date:  2019-12

2.  Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity.

Authors:  Joseph L Jilek; Kayla L Frost; Kevyn A Jacobus; Wenxi He; Erica L Toth; Michael Goedken; Nathan J Cherrington
Journal:  Acta Pharm Sin B       Date:  2021-06-02       Impact factor: 11.413

3.  Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer.

Authors:  Eoghan R Malone; Jeremy Lewin; Xuan Li; Wen-Jiang Zhang; Susan Lau; Keith Jarvi; Robert J Hamilton; Aaron R Hansen; Eric X Chen; Philippe L Bedard
Journal:  Cancer Med       Date:  2021-12-17       Impact factor: 4.452

4.  Mass spectrometry imaging and monitoring of in vivo glutathione-triggered cisplatin release from nanoparticles in the kidneys.

Authors:  Arthur C K Chung; Xuan Li; Wai-Chung Li; Tao Wang; Hin-Kiu Lee; Lijian Jin; Zongwei Cai; Ken Cham-Fai Leung
Journal:  Nanoscale Adv       Date:  2020-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.